Harmony Biosciences Holdings, Inc.

Lupin must wait until at least January 2030 to launch its proposed generic of Harmony Biosciences ’ Wakix (pitolisant hydrochloride) after agreeing to settle patent infringement litigation. The agre

Harmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down

Harmony Biosciences plans to accelerate Phase III development of a high-dose pitolisant formulation (pitolisant HD) in idiopathic hypersomnia (IH) after the US Food and Drug Administration turned down

“How does it feel that you have a billion-dollar neuroscience commercial business, and no one cares?” That’s the question an investor asked Alkermes’ chief operating officer Blair Jackson at the recen